Nancy A. Rigotti, MD, of the Tobacco Research and Treatment Center at Massachusetts General Hospital and Harvard in Boston, agreed in aneditorial accompanying the NEJM paper. However, getting the drug to the U.S. market could be a challenge, Rigotti told MedPage Today. The manufacturer in Bulgaria never saw a market for the drug in the U.S. and so never tried for approval, she explained. "We're sort of stuck here," she said in an interview.

With the start of the financial year the management of Sopharma AD parts with the company’s Commercial Director. Vladimir Stoychev joined the team of Sopharma AD in September 2001 as a warehouse manager for export goods. Later he was transferred to the position of Head of Kazahstan office. His good work lead eventually to his promotion to Commercial Director of Sopharma AD in 2007. The management team of the company wishes Mr. Stoychev success in his new professional endavoures. The Executive Director of the company will temporarily be responsible for the export markets.

Sopharma AD (the “Company”) announces that the Company sold 20 000 ordinary registered shares with voting rights, representing 0.107% of the share of the capital of United Holding Doverie AD. After this transaction the share of Sopharma AD in the capital of United Holding Doverie AD decreased below 15% to 14.93%.

Sopharma AD (the “Company”) notifies that in connection with the Easter Holiday the results for April 2013 will be published on 10 May 2013.

SOPHARMA AD (the “Company”) hereby informs that from 18 April 2013 up to and including 24 April 2013 the Company bought 140703 own shares representing 0.107% of the share capital of the Company, to the total value of BGN 355773.63 on the Bulgarian Stock Exchange. The average price per share was BGN 2.53.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4005668, representing 3.03% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 11 April 2013 up to and including 17 April 2013 the Company bought 158132 own shares representing 0.12% of the share capital of the Company, to the total value of BGN 405022.17 on the Bulgarian Stock Exchange. The average price per share was BGN 2.56.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 3864965, representing 2.93% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 4 April 2013 up to and including 10 April 2013 the Company bought 39486 own shares representing 0.03% of the share capital of the Company, to the total value of BGN 97648.86 on the Bulgarian Stock Exchange. The average price per share was BGN 2.47.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 3706833, representing 2.808% of the share capital of the Company.

SOPHARMA AD (the “Company”) hereby informs that from 28 March 2013 up to and including 3 April 2013 the Company bought 1000 own shares representing 0.00076% of the share capital of the Company, to the total value of BGN 2370 on the Bulgarian Stock Exchange. The average price per share was BGN 2.37.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 3667347, representing 2.778% of the share capital of the Company.

We would like to notify, that Sopharma AD received  the following opinion from Momina krepost AD:

On 27 March 2013, we received a notification pursuant to art. 151, par. 3 of POSA, accompanied by a tender offer under art. 149, par. 6 of POSA from Sopharma AD for purchasing of the shares of the remaining shareholders of Momina Krepost AD.

In accordance with art. 151, par. 5 of POSA and within the statutory period we present a motivated opinion regarding the tender offer.

І. Conditions of the tender offer

Sopharma AD (the “Company”) notifies that for March 2013 Sopharma AD realized a decrease of sales revenues of 10% compared to the same period of 2012, including 12% increase of domestic sales and 20% decrease of export sales.

During the past three months Sopharma AD recorded a decrease of sales revenues of 4%, including 5% increase of domestic sales and 8% decrease of export sales compared to 2012.